
æ¥æ¬æ¿åºãå€é¡ã®è³éæäŸïŒãã¯ã¯ãã³ã100æ¥ããã·ã§ã³ããäž»å°ããCEPI
æ¥æ¬ã¯ãªããããªã«ããéãããŒã¹ã§æ¬¡ã
ãšã¯ã¯ãã³ãæ¿èªããããã«ãªã£ãã®ã§ãããããã¯ã¯ãã³å®çšåã100æ¥ããã·ã§ã³ããäž»å°ããŠããCEPI ïŒCoalition for Epidemic Preparedness InnovationsïŒææçæµè¡å¯Ÿçã€ãããŒã·ã§ã³é£åïŒã«ã€ããŠèª¿ã¹ãŠãããšããã³ãããã¯æ¡çŽãIHRæ¹æ£ã«ãã€ãªããæ¥æ¬ã®ç«ã¡äœçœ®ãèŠããŠããŸãã
ã¯ã¯ãã³å®çšåã100æ¥ããã·ã§ã³ããšã¯ïŒ
æ°ããã¯ã¯ãã³ã次ã ãšæ¿èªãããäžã§ãã100æ¥ããã·ã§ã³ããšããèšèãåºãŠããããã«ãªããŸããïŒäžèšåç §ïŒã
ã100æ¥ããã·ã§ã³ããã©ãããåºãŠããã®ãé¡ã£ãŠã¿ããšã2021幎ã®G7ãµãããã§æå±ããããšããè³æããããŸããã
å€åçã®ããŒãžãããäžèšãžã®ãªã³ã¯ããããŸãã
100 æ¥ããã·ã§ã³éæã«åãã G7 ãžã®æèš
2021 幎 6 æã«è±åœã§éå¬ããã G7 ãµãããã§ãWHOããåœéçã«æžå¿µãããå ¬è¡è¡çäžã®ç·æ¥äºæ ïŒ PublicHealth Emergency of International Concern, PHEICïŒãã宣èšããŠãã 100 æ¥ä»¥å ã« MCMïŒå±æ©å¯Ÿå¿å»è¬åãMedial Countermeasures,ïŒã®å®çšåãéæããããšãç®æããã100 Days MissionïŒ100 æ¥ããã·ã§ã³ïŒããæå±ãããããšæžãããŠããŸãã
100æ¥ããã·ã§ã³ã®åèè³æãšããŠãäžèšã®URLã瀺ãããŠããŸãã
ãã®è³æã«æžãããŠããããCEPIïŒææçæµè¡å¯Ÿçã€ãããŒã·ã§ã³é£åïŒããšããããŒãããŒã·ãããæ°ã«ãªããŸããã
æ¥æ¬æ¿åºãå€é¡ã®è³éæäŸããŠããCEPIãšã¯ïŒ
調ã¹ãŠã¿ããšã2022å¹Žã«æ¥æ¬æ¿åºãCEPIã«ã3åãã«æ åºãããšèªçŽããããšãããªãªãŒã¹ããããŸããã
æ¥æ¬æ¿åºã CEPI ã®ãã³ãããã¯å¯Ÿçèšç»ã«3 åãã«ã®æ åºãèªçŽ
2022 幎 2 æ 25 æ¥
远èšïŒæ¥æ¬èªçã®ãªãªãŒã¹ãåé€ãããŠããŸã£ãããã§ãã
è±èªç
以äžããªãªãŒã¹ããäžéšåŒçšã§ãã
CEPI ã«ã€ããŠ
CEPI ã¯ãå°æ¥èµ·ããåŸãææçã«å¯Ÿããã¯ã¯ãã³ãéçºããããã2017 幎ã®ããã¹äŒè°ã§çºè¶³ãããå ¬çæ©é¢ãæ°éäŒæ¥ãæ åå£äœãåžæ°å£äœãªã©ã飿ºãã驿°çãªããŒãããŒã·ããã§ãã
ãªãã£ãŒãã»ããã§ãã CEPI æé«è²¬ä»»è ã®ã¡ãã»ãŒãžïŒ
ãæ¥æ¬æ¿åºã¯ããã¹ãŠã®äººãå®å šã§ãªããã°èª°ãå®å šã§ã¯ãªããšãã䜿åœã以åããèªèããæ¯æŽããŠãã ãã£ãŠããŸããæ¥æ¬ã¯ã2016 幎ã«åæããããåœéä¿å¥ã®ããã® G7 äŒå¢å¿æ©ããžã§ã³ãã§ CEPI åµèšã®éçãã€ããåœã§ããŸã CEPI åµèšæã®è³éæäŸåœã§ããããŸããCEPI ã®æåã¯ãæ¥æ¬ã®çããã«ãããšãããéåžžã«å€§ãããªã£ãŠããŸããæ¥æ¬ã®äººã ãšäžçã®äººã ãæ¥ãã¹ããã³ãããã¯ããå®ãããã«æ¬ ããããšã®ã§ããªããã®æè³ã«ã€ããŠãå²žç°æéå é£ç·ç倧è£ã«åŸ¡ç€Œç³ãäž
ããŸãã
CEPI æé«è²¬ä»»è ã¯ãæ¥æ¬ãã CEPI åµèšã®éçãã€ããåœãã ãšèšã£ãŠããŸãã
ããã¹ãŠã®äººãå®å šã§ãªããã°èª°ãå®å šã§ã¯ãªããšãã䜿åœããšããã®ã¯ãã©ã®ç«å Žã§èšã£ãŠããã®ã§ãããããã¯ã¯ãã³æ¥çš®åŸã«æ»äº¡ãããå¥åº·è¢«å®³ã§èŠãã人ãããã®ã«ã广ããããšãã£ãŠæ¥çš®ãæšå¥šããããšãšççŸããŠããŸãã
ååŽçã®ãµã€ãã«ããCEPIã«é¢ãããªãªãŒã¹ïŒä»€å4幎2æ25æ¥ä»ïŒããããŸããã
ãïŒæïŒïŒæ¥ãå²žç°æéç·ç倧è£ã¯ãåœéçãªã¯ã¯ãã³ã®éçºã»è£œé ãæ ãCEPIïŒææçæµè¡å¯Ÿçã€ãããŒã·ã§ã³é£åïŒã®ãªãã£ãŒãã»ããã§ããCEOãšé»è©±äŒè«ãè¡ããCEPIã«å¯ŸããŠãæ¥æ¬æ¿åºãããä»åŸïŒå¹Žéã§ïŒåãã«ã®æ åºãæ°ãã«è¡ãããšãäŒãããšãšãã«ãçŸäžã®æ°åã³ãããžã®å¯Ÿå¿åã³å°æ¥ã®ãã³ãããã¯ãžã®åãã®ããã«ãCEPIãšã®é£æºã匷åããŠããããšã確èªããŸããã
ãCEPIã«å¯Ÿããè²¢ç®ã¯ããã³ãããã¯ãšãã人é¡å ±éã®èª²é¡ã«å¯Ÿå¿ããäžã§å€§ããªæçŸ©ãæãããã®ã§ããããŸããæãåœèªèº«ã®ã¯ã¯ãã³éçºã»è£œé ãäžå±€ä¿é²ããäžã§ã®äžå©ãšãªãåŸãŸãã
ãä»åŸãšããæ¥æ¬æ¿åºã¯ãåœé瀟äŒã®ã¯ã¯ãã³éçºåã³è£œé ã«ç©æ¥µçã«è²¢ç®ããŠãããŸãã
ååŽçãçºè¡šããŠããŸãããããããåãäžãããã¬ãå±ã¯ãã£ãã®ã§ããããã
æåã«åãäžãããCEPIã®ãªãªãŒã¹ã«æ»ããŸãã
æ¬æ¥ã®æ¥æ¬æ¿åºã®èªçŽã¯ã3 æ 7ïœ8 æ¥ã«éãããã°ããŒãã«ãã³ãããã¯å¯Ÿçãµãããã«å é§ãããã®ã«ãªããŸããè±åœæ¿åºãšã®å ±åéå¬ãšãªããµãããã¯ãCEPI ã® 35 åãã«èŠæš¡ã® 5 ã幎èšç»ã«å¿ èŠãªè³éãéããããšãç®çãšããŠããŸãããã® 5 ã幎èšç»ã¯ã驿°çã§ã¢ã¯ã»ã¹ã«ãã©ãŒã«ã¹ããç ç©¶éçºããã°ã©ã ãå¯èœã«ããæ°ããçŸç ãšéãããã®å®å šã§å¹æçããã€äžçäžã§ã¢ã¯ã»ã¹ã§ããã¯ã¯ãã³ãããã 100 æ¥ã§éçºããããšãä¿é²ããããšãç®çãšããŠããŸãã
ïŒäžç¥ïŒ
CEPI ã®æå€§è³éæäŸåœã®äžã€ãšããŠãæ¥æ¬ã¯ãã³ãããã¯å¯Ÿçãšæ°åã³ããææç察å¿ã«ãããŠäžå¿çãªæšé²åãšãªã£ãŠããŸãããã® 2 幎éãCEPI ãå ±åã§äž»å°ãã COVAX ãå«ããã¯ã¯ãã³æ¥çš®ãé²ããå€åœéååãžã®æ¥æ¬ããã®æ¯æŽã¯éåžžã«éèŠã§ãããã¢ãã«ããã¢ã¹ãã©ãŒãã«ãæ¥æ¬ã§ãçç£ãå§ãŸãäºå®ã®ããããã¯ã¹ãªã©ã®ã¯ã¯ãã³éçºã«å¯Ÿã㊠CEPI ãåææè³ãã§ããã®ããæ¥æ¬ãªã©ã«ããæ¯æŽã®ãããã§ããã
ç®æšãšããã®ã¯ãå®å šã§å¹æçãªæ°åã³ãããŠã€ã«ã¹ææçã¯ã¯ãã³
åè£ã®å€æ§ãªããŒããã©ãªãªã®èšåºéçºãä¿é²ããCOVAX ãéããŠãããã®ã¯ã¯ãã³ãäžçã«å ¬å¹³ã«åé ã§ããããã«ããããšã§ãã
CEPI ã® 5 ã幎èšç»ã¯ã35 åãã«ã®ããŒãããããšããŠãã¯ã¯ãã³éçºæéã 100 æ¥ã«ççž®ããæ°åã³ãããŠã€ã«ã¹ææçãšä»ã®ããŒã¿ã³ãããŠã€ã«ã¹å±ææçã«åºç¯ã«å¯Ÿå¿ã§ããã¯ã¯ãã³ãéçºããæ¢ç¥ãšæªç¥ã®ç åäœã«å¯Ÿå¿ããã¯ã¯ãã³åè£ã®ã ã©ã€ãã©ãªãŒ ããäœããšã ããã®ã§ã ã
35 åãã«èŠæš¡ã® 5 ã幎èšç»ãªã©ã«ã€ããŠã¯ãäžèšã®ãµã€ãã«è©³ããæžãããŠããŸãã
CEPIã®äž»èŠã¡ã³ããŒãæ¯æŽå£äœã«ã€ããŠãæžãããŠããŸãã
Since its launch in 2017, CEPI has forged partnerships with over 30 vaccine developers, manufacturers, and academic institutions. 30 countries, in addition to the European Commission, are now members of our coalition as well as the key philanthropic organisations the Bill & Melinda Gates Foundation and Wellcome Trust. It has also been supported by a number of private organisations.



ãµã€ãã®æ¥æ¬èªèš³ããããŸããããå
šéšèš³ãããŠããããã§ã¯ãªãããã§ãã
https://cepi.net/wp-content/uploads/2021/11/CEPI-Investment-Case-Japanese_MARCH2021.pdf
äžèšã®è³æã«ã¯ãããŒãã¡ã³ããŒïŒæ¥æ¬äººãå«ãïŒãè³éæäŸã®éé¡ãªã©ãæžãããŠããŸãã
2020幎ç
BOARD OF DIRECTORSâ REPORT AND ANNUAL ACCOUNTS 2020

CEPIÂŽs mission is to accelerate the development of vaccines against emerging infectious diseases and enable equitable access
to these vaccines for affected populations during outbreaks.
CEPI ã®ããã·ã§ã³ã¯ããæ°èææçã«å¯Ÿããã¯ã¯ãã³éçºãå éããããšãã ãšã¯ã£ãããšæžãããŠããŸãã
2021幎ç
Board of Directors' Report and Annual Accounts 2021



2022幎ç
Board of Directors'Report and AnnualãAccountsã2022



CEPIã®ç®æšã¯ãå®å šã§å¹æçãªæ°åã³ãããŠã€ã«ã¹ææçã¯ã¯ãã³åè£ã®å€æ§ãªããŒããã©ãªãªã®èšåºéçºãä¿é²ããCOVAX ãéããŠãããã®ã¯ã¯ãã³ãäžçã«å ¬å¹³ã«åé ã§ããããã«ããããšããšã®ããšã§ããããå®å šãã¯ã©ããã«è¡ã£ãŠããŸã£ãŠããŸãã
ã¹ããŒãéèŠã§ã¯ã¯ãã³éçºãé²ãããããéäžåœã«ãåºããããšããŠããã®ã§ããCEPIãããããšããŠããããšã¯ãæ¬åœã«ãéäžåœã®ããããªã®ã§ããããã
ãã³ãããã¯æ¡çŽã§ããã¯ã¯ãã³ãžã®å
¬å¹³ãªã¢ã¯ã»ã¹ãã®ããã ãšèšã£ãŠããŸãããæ¬åœã«éäžåœã®ãããæããªãããŸãã³ããã¯ã¯ãã³ã«ãã£ãŠèµ·ããå¥åº·è¢«å®³ããã£ãããšèª¿ã¹ãã¯ã¯ãã³ã®ãªã¹ã¯ããã¡ããšéäžåœã«ç¥ãããã¹ãã§ã¯ãªãã®ã§ããããã
第6åãå é²çç ç©¶éçºæŠç¥ã»ã³ã¿ãŒæŠç¥æšé²äŒå
æç§çã®è³æã«ããCEPIã«ã€ããŠèª¬æããããŸããã
ã第6åïŒä»€å5幎8æ2æ¥ïŒé ä»è³æ


2017幎ïœ2022幎ã®5ã«å¹Žèšç»ïŒCEPI 1.0ïŒã«æ¥æ¬ã¯2.2åãã«ïŒå šCEPIã®èª¿éè³éã®16.7ïŒ ïŒãæ åºãããããã«2023幎ããã®5ã«å¹Žèšç»ïŒCEPI 2.0)ã«3åãã«ïŒçŽ345ååïŒãæ åºããããšãèªçŽããŠããã
åœæ°ã«ãã¡ããšèª¬æãããã«ãæ¥æ¬ã¯ãããªã«å€é¡ã®è³éæäŸãããŠããã®ã§ãããããã£ãŠæ å ±ã¯å ¬éããŠããŸãããããã§ã¯ç¥ãããããšã«ã¯ãªããªããšæããŸããæ·±ãåãããŠããã®ã§ãæãèµ·ãããªããšèŠã€ããããšã¯ã§ããŸããã
ãããŠãç«ã¡æ¢ãŸã£ãŠå®å šæ§ã«ã€ããŠæ€èšŒããã©ããããããŠãããŒãµã«åãã³ããã¯ã¯ãã³ã®éçºãé²ããããŠããŸãã

ãã§ã«èšåºè©Šéšãé²ãã§ããŸãã

ãããã®éçºã¯ããã£ãã誰ã®ããã«è¡ãããŠããã®ã§ããããã